Inhibikase updates September 2026 corporate presentation; no new financial or pipeline details disclosed

Inhibikase Therapeutics, Inc.

Furnished updated corporate presentation dated September 2026 for investor, analyst, and other meetings.
Reported September 8, 2026; signed by CEO Mark Iwicki.
Available exhibit text contains only a standard disclaimer; no specific financials, pipeline data, or milestones included in filing excerpt.
Presentation furnished under Regulation FD; common stock trades as IKT on Nasdaq.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.